I
'n experimental murine cutaneous leishmaniasis caused by Leishmania major (Lm) 1, disease outcome in genetically resistant and susceptible mice is modulated by preferential expansion of either protective or exacerbative T cells, respectively (1, 2) . However, it remains unclear which cell populations govern the preferential activation of exacerbative or protective T cell subsets. It is known that T cell differentiation 1 Abbreviations used in this paper: ATXBM, adult thymectomized lethally irradiated, bone marrow-reconstituted; GvHR, graft-versus-host reactions; Lm, Leishmania major; LNC, lymph node cells; Mq~, macrophage; miHA, minor histocompatibility antigens. and function can be influenced by the qualities of both T cells themselves and APC (3, 4) . Several studies of murine leishmaniasis have, indeed, demonstrated that, in addition to T cells, differences in the function of APC, such as macrophages (M~) (5) (6) (7) (8) and B cells (9, 10) , may influence disease outcome. Thus, it is conceivable that the fate of infection may be determined by either T cells, non-T cells such as APC, or a combination of the two. Identification of the cellular compartments influencing disease outcome would be useful since such knowledge could facilitate a rational approach toward immunotherapy and vaccination.
Therefore, we conducted studies examining the contribu-tion of T cell and non-T cell factors to the development of immunity in genetically resistant, C57BL/6, and susceptible, BALB/c, mice. This was accomplished by constructing two groups of reciprocal T cell chimeric animals through recombination of T cell-deficient adult thymectomized lethally irradiated, bone marrow-reconstituted (ATXBM) hosts of C57BL/6 or BALB/c background with naive H-2-congenic T cells of BALB/c or C57BL/6 background, respectively. Mice were then infected with Lm, and disease progression was monitored through lesion size, parasite numbers, cytokine production, and TCR VB usage of Lm-specific T cells.
Materials and Methods
Animals. All mice were purchased as specific pathogen-free young adults and maintained in accordance with National Institutes of Health guidelines. BALB/c and C57BL/6 thymectomized animals were prepared by adult thymectomy of 3-wk-old animals by Taconic Farms (Germantown, NY) and were provided with agematched euthymic control mice. Animals used as bone marrow and thymocyte donors were from either Taconic Farms, the National Cancer Institute (Rockville, MD), the Jackson Laboratory (Bar Harbor, ME) for B6.C-H-2a/aBy mice, or Harlan Olac Ltd. (Bi-B220 RA3-3A1 cester, United Kingdom) for C.B6-H-2 b mice. CD4 GK1.5 Parasites and Antibodies. Lm was a done of LV39 and was maintained as previously described (11) . The mAbs used in this study CD8 H35-17.2 are listed in Table 1 Table 2 . Control and thymectomized mice were maintained on acidified water, pH 2.5-3.5, for at least 6 wk before it-IL-4 BZD6-24G2 radiation and throughout the experiment. BALB/c and C57BL/6 IL-10 JES5-2A5 mice were lethally X-irradiated with 850 and 900 rads, respectively, IL-10 SXC-1 at a dose rate of 25 rads/min. 6 h later they were reconstituted Ly-6A. (37) . Lesion VB9 MRIO-2 progression was followed by measurement of footpad swelling with VB10 KT10b-2 a vernier caliper using the uninfected contralateral footpad as a con-V~I 1 RR3-15 trol. Parasite numbers in footpads, spleens, or draining (popliteal, inguinal, and para-aortic) lymph nodes of infected mice were de-VB13 MR12-4 termined with duplicate mice at the indicated time points using V/~14 14-2 a limiting dilution assay (38) .
Analysis of Reconstitution Status and Chimerism.
To examine reconstitution status, duplicate mice were killed and the draining lymph nodes or spleens were prepared as a single cell suspension. Lymphocytes were stained for expression of Thy-1, CD4, CDS, B220, and Mac-l, and analyzed by flow cytometry using a FACScan | (Becton Dickinson & Co., Mountain View, CA), as previously described (39) . Gating was adjusted to include lymphocytes and monocytes, while excluding cells with high side scatter, such as granulocytes. All analyses were performed on 5,000 gated events.
To confirm that the responding T cells in chimeric animals were of donor origin, Lm-spedfic T cell bhsts from draining lymph nodes were obtained through one cycle of stimulation, rest, and restimulation, as previously described (40, 41) , using live Lm and fresh irradiated spleen ceils of host genotype. T cell blasts were assayed for chimeric status after the first or second restimulation in vitro. Cells were stained with anti-CD4 or normal rat Ig, followed by PE-goat anti-rat IgG preabsorbed with mouse Ig (Southern Bio- • 106 fresh lymphocytes from draining lymph nodes were stimulated with 2 x 106 live Lm in 0.5 ml/well on 48-well tissue culture plates (Costar). In all cases, supernatants were harvested after 24 h, which was previously determined to be a point at which reliable and representative results could be observed in this system (40) . IL-4 and IFN-3, activity in supernatants was detected by either bioassay, using the 11.6 and WEHI cell lines as previously described (39, 40) , or by sandwich ELISA performed on Maxisorp | F96 plates (Nunc, Roskilde, Denmark) with capture mAbs 11Bll, R4-6A2, and secondary biotinylated mAbs BZD6-24G2 and XMG1.2 (PharMingen, San Diego, CA), respectively. Binding of the secondary mAb was detected using a streptavidin-horseradish peroxidase conjugate (Sigma). II.-10 was also detected by sandwich ELISA using the capture mAb JES5-2A5 in conjunction with rat IgM mAb SXC-1. Binding of the secondary mAb was detected using horseradish peroxidase-conjugated goat anti-rat IgM (Pierce Chemical Co., Rockford, IL). ELISA's were developed with 3, Y, 5, 5' -tetramethybenzidine peroxidase substrate (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD). In all cases, cytokine concentrations were reported as units per milliliter and were calculated from a standard curve for each assay obtained with known concentrations of recombinant cytokines (Genzyme Corp., Cambridge, MA).
VflAnalysis. Lm-specific blasts were isolated and stained with supernatants of hybridomas secreting the appropriate anti-VB mAb, and analyzed by flow cytometry as described above. Negative controls consisted of the appropriate species and isotype matched mAb or normal Ig. The secondary antibodies were FITC-labeled goat anti-IgG(-IgM) for either mouse (Cappel-Organon Teknika, Durham, NC), rat (Tago, Inc., Burlingame, CA), or hamster (Caltag Laboratories, San Francisco, CA).
Absence of Graft-versus-Host Reactions (GvHR). The absence of
GvHR was confirmed through monitoring chimeric and control animals for external signs of GvHR, such as mortality, weight loss, alopecia, and dermatitis. All sacrificed mice were inspected for gross internal GvHR pathologies, such as enteritis and hypersplenomegaly. Finally, fresh lymph node cells (LNC) from chimeric and control animals were stimulated in vitro with allogeneic spleen cells, and cytokine production and proliferation were assessed. For cytokine production, 2.5 x 106 LNC and 2.5 x 106 irradiated spleen cells of host genotype were cultured in 0.5 ml of medium for 24 h, as previously described (39) . Culture supematants were then examined for the presence of IFN-3, and IL-4 by ELISA, as detailed above. For proliferation, cells were stimulated in vitro by incubating 5 x 10 s LNC with 5 x 105 irradiated spleen cells as described elsewhere (39) .
Results
Disease Outcome in T Cell Chimeric and Control Mice. Disease outcome with respect to lesion size is shown in Fig. 1, A and/~ In the BALB/c set ( Fig. 1 A) , we observed, as expected, that both euthymic CT + and sham chimeric CT-+ C mice succumbed to infection and required euthanasia by day 55, due to severe ulcerated and necrotic lesions. In striking contrast, chimeric CT-+B6 animals, reconstituted with naive thymocytes from resistant B6.C-H-2 d mice, resolved their infections. Lesion progression in the C57BL/6 set ( Fig. 1  B) showed the expected cure of control groups B6T + and B6T-+B6. Interestingly, chimeric B6T-+C mice, given thymocytes from susceptible C.B6-H-2 b animals, also cured with similar kinetics. We next determined parasite burdens in lesions of infected CT-+ C animals, resulting in metastasis to lymph nodes and spleen by day 30 (Fig. 1 C) . However, in agreement with lesion development, chimeric CT-+B6 animals reduced their parasite burdens 1,000-fold by day 80 and showed no signs of parasite dissemination. For the C57BL/6 set, again in agreement with lesion size, all three groups reduced their parasite burdens (Fig. 1 D) . Finally, as an additional control, we examined the outcome of Lm infection in CT-and B6T-mice which received no T cells. These animals experienced dissemination of the parasite to the spleen and lymph nodes by day 30. More importantly, parasite growth was unrestrained such that by day 80 more than 80 x 106 and 95 x 106 Lm/footpad were observed in CT-and B6T-mice, respectively.
Verification of Reconstitution and Chimeric Status.
To interpret these results, it was necessary to verify that reconstitution of the lymphoid system had occurred and that T cells mediating disease outcome in chimeric mice were of donor origin. Flow cytometric analysis of lymphocytes from the draining lymph nodes revealed that reconstitution was achieved for T cells, B cells, and MOs (Table 3) . Similar cell compositions were observed in the spleen, suggesting that lymphoid reconstitution was systemic and not limited to immunologically active areas. Moreover, total cell counts were similar in each group of thymectomized control and chimeric animals. The fact that animals with virtually identical lymph node composition, Cx-+C and CT-+B6, exhibited divergent disease outcomes (Fig. 1 , A and C) demonstrates that ample cell numbers were present to support the full spectrum of disease.
To determine whether T cells mediating disease outcome were of donor origin, Lm-specific T cell blasts were generated from chimeric animals and analyzed for expression of allelic markers Ly-6E.1 or Ly-6A.2, expressed by either the BALB/c or C57BL/6 genotype, respectively (43) . Results (Fig.  2) indicate that all responding T cells were of donor origin in both groups of T cell chimeric mice. Cr § C-r-+C larly, the resistant C57BL/6 control B6T § and B6T-+B6 animals developed the expected Thl-type profile of normal C57BL/6 mice ( Fig. 3, bottom; reference 40) . Cytokine production in chimeric B6T-+ C animals, however, displayed a novel pattern. IFN-3, levels increased until the middle phase of infection and, subsequently, declined to lower levels by day 80. This was accompanied by high IL-4 production throughout infection, and IL-10 levels which declined until the middle phase and then rebounded by day 80. Thus, chimeric B6T-+C mice exhibited a Th0 cytokine pattern (IFN-3'hill.r4hilL-10 hi) which progressively approached a Th2 profile as cure ensued. Although most cytokine analyses were performed on Lm-spedfic T cell populations expanded in vitro, similar results were found when draining LNC were stimulated with Lm. 
Cytokine Production ofT Cell Chimeric and Control Mic~

Analysis ofT Cell V~ Usage of Lm-specific T Cells.
One potential factor influencing disparate T cell development and function in leishmaniasis could be antigen specificity. Since this would be echoed in the TCR usage of Lm-specific T ceils, we examined the V3 repertoire of responding CD4 + T ceils in control and chimeric mice (Fig. 4) . In the BALB/c set, no consistent differences in V3 usage were observed between ceils from curing CT-+B6 and noncuring CT + and CT-+C mice (Fig. 4, top) . Within the C57BL/6 groups, V3 usage was also found to be similar (Fig. 4, bottom) . Since normally noncuring T ceils from the C.B6-H-2 b mouse mediated cure in a B6 environment (Fig. 1) , we reasoned that certain protective antigens may not be presented to T cells in noncuring animals. We, therefore, analyzed the V3 usage in C.B6-H-2 b mice and again found it to be similar to mice in the C57BL/6 group (Fig. 4, bottom) . Thus, despite the fact that C.B6-H-2 b T cells were exacerbative when operating within the susceptible host and curative in the resistant host, the VB repertoire remained similar. In all mice, V3 usage was multiclonal, involving primarily V32, 4, 6, 8.1, 8.2, 8.3, 10, and 14. The most pronounced differences found in this analysis were that V3 usage among H-2a-restricted Lm-specific T cells (Fig. 4, top) involved more V38 and fewer unscreened V3 segments as compared to cells from H-2 b mice (Fig. 4, bottom) .
GvHR Is Not Detectable in Chimeric Animals. Given that this experimental system involved donor T cells and recipient hosts which are congenic only at the major histocompatibility loci, it is possible that GvHR against minor histocompatibility antigens (miHA) might occur and potentially influence our results. We, therefore, tested for presence of GvHR in chimeric animals ( Table 4 ). As indicated, no pathology typical of GvHR, such as mortality, weight loss, alopecia, dermatitis, bowel inflammation, or hypersplenomegaly, could be detected in chimeric animals. Furthermore, coculture of LNC from chimeric animals with miHA allogeneic spleen cells failed to elicit proliferation or cytokine production of either Ib4, or, more importantly, IFN-3', which is produced in GvHR against miHA (44) . These results indicate that chimeric animals were free of GvHR by all parameters examined.
Discussion
The results of this study show that the BALB/c environment clearly supported a curative outcome when supplied with naive B6-type T cells. Several studies have indicated that early IFN-3' production is necessary, though not sufficient, for cure (4, (45) (46) (47) . Our results imply that B6-type T cells may produce, and/or elicit from other cells, sufficient IFN-y production for disease resolution. Since it has been shown that depletion of NK or y~5-T cells did not reverse disease Cytokine response to allogeneic spleen cells:S IFN-3, (U/ml _+ SE) 2.5 _+ 2.0 0.0 -+ 0.6 IL-4 (U/ml _+ SE) 0.0 _+ 1.6 0.6 -+ 2.5
Control (C-r-+C, B6-r-+B6) and chimeric (CT-+B6, B6"r-+C) animals were assessed for the various parameters indicative of GvHR as outlined in Materials and Methods. * Mortality represents cumulative deaths calculated from the time that thymocyte infusions began until the end of the experiment (~120 d).
Control mice reflect mortality in only the B6T-+B6 group since CT-+ C mice succumbed to infection. Data are reflective of all seven experiments conducted. * Control and chimeric mice reflect B6T-+ B6 and B6T-+ C groups, respectively, weighed 140 d after reconstitution. S Representative data obtained from popliteal and inguinal LNC from duplicate control (CT-+C) and chimeric (CT-+B6) mice analyzed 10 wk after reconstitution. Chimeric LNC also failed to proliferate in the presence of allogeneic spleen cells, but did respond to Con A.
outcome in resistant mice (48, 49) , conventional T cells may well be the crucial source of early IFN-y. In the early phase of infection, IL-12 has been shown to be an important cytokine in determining resistance (50, 51) . Thus, as for IFN-3,, B6-type T cells may elicit IL-12 production from other cells, such as NK cells or Mq's. In contrast, the potentially exacerbative properties of the BALB/c environment, such as B cells (9), production of TGF-~ (52, 53) or IL-10 (54-56), could not in and of themselves override the autonomous curing ability ofB6-type T cells. It appears, therefore, that the exacerbative T cell response in BALB/c mice results from a unique interaction between its T cell and non-T cell compartments. It will be informative to determine if the Lm-susceptibility of mouse strains SWR/J (57), NZW/N, P/J, and C57L/J (7) is also influenced by such interactions. With regard to the resistant B6 environment, we observed that normally noncuring BALB/c-type T cells could mediate cure in the B6 milieu. Clearly, the B6 environment did engender substantial IFN-3, production from BALB/c-type T cells, which do not normally produce such high levels. Thus, the propensity for IFN-3, production in B6 mice appears to be rooted at both the T cell and non-T cell levels. Again, ILo12 production by the resistant environment may be a key factor given that early presence of IL-12 can reverse susceptibility in BALB/c mice (50, 51) . Interestingly, the B6 milieu was unable to downregulate IL-4 production by BALB/c-type T cells. The mechanism(s) whereby the B6 environment promotes development of protective T cells must, therefore, be refractory to the exacerbative effects of IL-4. Two other studies have found little effect of infusing IL-4 into resistant mice (58, 59) . Still, in one recent study, normally resistant mice were rendered susceptible by an IL-4 transgene constitutively expressed in B cells (60) . Given the controlled design of chimeric mouse studies, however, the data herein represent the strongest indication to date that neither IL-4 production, nor the onset of a Th2 cytokine profile, is sufficient to promote disease. In fact, they can accompany a curative outcome.
It will be interesting to determine how Th2 cells can be involved in resistance. Th2 cells have been shown to perform some Thl functions such as delayed-type hypersensitivity (61), isotype switching for IgG2a production (61) , and destruction of Lm (62) . It is, therefore, conceivable that a subset of Th2 cells shares Thl functions related to control of Leishmania. It appears that these Th2 cells may be preferentially stimulated in B6T-+C chimeric mice. It remains a paradox that, despite significant correlations between Thl responses and cure, and Th2 responses and disease progression (63) , the Th phenotype, itself, has not been a reliable predictor of protective or exacerbative function (41, 62, (64) (65) (66) . The results of this study further imply that significant overlap exists with regard to Thl and Th2 cell function in experimental murine leishmaniasis caused by Lm.
The uncertain division of Thl and Th2 functionality may be rooted in the diverse roles of IL-4, IL-IO, and IFN-y in cutaneous leishmaniasis (64, 67) . Some studies have indicated a protective role for IL-4 (68), particularly late in infection (69) , while others describe exacerbative (46, 63, 64, 67) or negligible effects (58) (59) (60) . Hence, it is uncertain if IL-4 is, itself, exacerbative in BALB/c mice or simply acts as a growth factor for exacerbative Th2 cells. Similarly, IL-IO can potentiate both exacerbative (54) (55) (56) and protective (70) functions. Finally, IFN-y has been associated with protection (45, 46, 63, 64, 67) and exacerbation (41, 65) . Our results underscore the pleiotropic nature of cytokines, whose functions are defined by the overall milieu in which they act. In this context, it may be useful to examine the broader roles of other cytokines shown to be protective in leishmaniasis, such as IL-12 (50, 51) , TNF (71-74), macrophage inflammatory proteins 1 and 2 (64), and IFN-ot (75, and Shankar, A. H., unpublished observations).
The results of the V3 analysis are consistent with the presumption that differential V3 usage is not responsible for disparate disease outcomes. This conclusion is supported by other work in which TCR V3 analysis in Lm-infected curing and noncuring strains was performed (76) . Nevertheless, such analyses must be interpreted with caution since, in the absence of data reflective of complete T cell receptor sequences at the population level, one cannot determine if fine specificities are critical. The data presented here indicate that V~ usage among Lrn-specific cells is multiclonal, using predominantly VB2, 4 (Fig. 4) . In contrast, results from the previous study singled out VB4 beating cells as predominant responders with H-2 b and H-2 d mice having similar repertoires. Such differences may be due to the different T cell populations studied. We examined the repertoire of enriched CD4 + Lmspecific T cell populations as compared to the total CD4 + population from draining lymph nodes of Lm-infected mice used in previous work (76) .
Disease outcome in murine Lm infection is determined by bone marrow-derived cells (77) . Although B cells and macrophages (5-10) have been previously implicated as the hematopoietic lineages determining disease outcome, this study suggests that T cells, themselves, can play a pivotal role. This is not unprecedented as it has been shown that resistance to an intracellular bacteria of macrophages, Rickettsia tsutsugumashi, is determined at the level of the T cell by the ETA-1 locus (78) . Lastly, given that the difference in Lm-susceptibility between the BALB/c and C57BL/6 strains is most likely governed by a single locus (57, 79, 80) , the results of our study imply that this locus affects more than one lineage of cells.
The parsimonious interpretation of the data presented here is that T cell and non-T cell factors can independently direct a curative outcome to Lm infection. Two potential alternative interpretations are addressed in Tables 3 and 4 . First, Table  3 indicates that insufficient reconstitution could not account for the results since the full spectrum of disease was displayed by equally reconstituted CT-+B6 and CT-+C mice. Previous work with BALB/c SCID mice indicated that "~35 x 106 T cells were sufficient to restore the susceptible phenotype (81) . The actual number, however, may be considerably lower since effective reconstitution would be limited by the lack of high endothelial venules in SCID mice (82) . We observed that '~30-45 x 106 mature BALB/c thymocytes engrafted into genetically normal BALB/c ATXBM recipients were more than sufficient to restore susceptibility. This number should apply to congenic thymocytes as well since it has been shown that T cells from BALB/c and C57BL/6 mice respond equally to Lm antigen presented by H-2 congenic APC of either genotype (40) . Secondly, the data presented in Table  4 suggest that GvHR did not influence our results. The absence of GvHR is consistent with several other systems in which peripheral tolerance to minor histocompatibility antigens (miHA) was achieved postthymically (83) (84) (85) . Previous work has demonstrated that peripheral tolerogenic mechanisms can be potentiated after irradiation and bone marrow reconstitution such that GvHR across miHA are suppressed in allogeneic chimeras (86, 87) . In addition, other studies have suggested that emergent thymocytes, as compared to mature T cells, are particularly receptive to tolerogenic signals encountered in the periphery (88, 89) . Therefore, we constructed the T cell chimeras used here by infusing fresh thymocytes into irradiated hosts shortly after bone marrow reconstitution, thereby maximizing the establishment of a tolerogenic environment to miHA.
In conclusion, these data indicate that both T cell and non-T cell compartments influence cure and noncure outcomes of experimental murine cutaneous leishmaniasis caused by Lm. Secondly, cure can be effected independently from either compartment. Thirdly, continuous and profuse production of IL-4 is not sufficient to prevent healing and can even accompany cure. Finally, the mechanism through which resistance is conferred, by either T cell or non-T cell compartments, does not result in differential selection of V~ repertoires. These results are critical for antileishmanial vaccine development since they imply that variations in both the T cell and antigen presenting cell environment of the recipient must be considered. In a broader sense, these studies indicate that determinants of Thl and Th2 cell activation are distributed properties, encompassing T cell-dependent factors and elements of the surrounding milieu, such as APC.
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